BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 17726864)

  • 1. [Prognostic significance of microvessel density in ovarian cancer].
    Rossochacka-Rostalska B; Gisterek IJ; Suder E; Szelachowska JK; Matkowski RA; Lacko A; Kornafel JA
    Wiad Lek; 2007; 60(3-4):129-37. PubMed ID: 17726864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression of selected angiogenesis markers and modulators in pre-, peri- and postmenopausal women with ovarian cancer].
    Bednarek W; Mazurek M; Cwiklińska A; Barczyński B
    Ginekol Pol; 2009 Feb; 80(2):93-8. PubMed ID: 19338204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microvessel density assessment in benign and malignant endometrial changes.
    Czekierdowski A; Czekierdowska S; Czuba B; Cnota W; Sodowski K; Kotarski J; Zwirska-Korczala K
    J Physiol Pharmacol; 2008 Sep; 59 Suppl 4():45-51. PubMed ID: 18955753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.
    Rubatt JM; Darcy KM; Hutson A; Bean SM; Havrilesky LJ; Grace LA; Berchuck A; Secord AA
    Gynecol Oncol; 2009 Mar; 112(3):469-74. PubMed ID: 19135712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative evaluation of microvessel density determined by CD34 or CD105 in benign and malignant gastric lesions.
    Ding S; Li C; Lin S; Yang Y; Liu D; Han Y; Zhang Y; Li L; Zhou L; Kumar S
    Hum Pathol; 2006 Jul; 37(7):861-6. PubMed ID: 16784986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endoglin (CD105) is a useful marker for evaluating microvessel density and predicting prognosis in esophageal squamous cell carcinoma.
    Sakurai T; Okumura H; Matsumoto M; Uchikado Y; Owaki T; Kita Y; Setoyama T; Omoto I; Kijima Y; Ishigami S; Natsugoe S
    Anticancer Res; 2014 Jul; 34(7):3431-8. PubMed ID: 24982351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endoglin is a better marker than CD31 in evaluation of angiogenesis in glioblastoma.
    Behrem S; Zarkovic K; Eskinja N; Jonjic N
    Croat Med J; 2005 Jun; 46(3):417-22. PubMed ID: 15861521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Density of microvessels positive for CD105 (endoglin) is related to prognosis in meningiomas.
    Barresi V; Cerasoli S; Vitarelli E; Tuccari G
    Acta Neuropathol; 2007 Aug; 114(2):147-56. PubMed ID: 17594108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological significance and prognostic role of microvessel density, evaluated using CD31, CD34, and CD105 in prostate cancer patients after radical prostatectomy with neoadjuvant therapy.
    Miyata Y; Mitsunari K; Asai A; Takehara K; Mochizuki Y; Sakai H
    Prostate; 2015 Jan; 75(1):84-91. PubMed ID: 25307287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD105 expression is an independent predictor of survival in patients with endometrial cancer.
    Erdem O; Taskiran C; Onan MA; Erdem M; Guner H; Ataoglu O
    Gynecol Oncol; 2006 Dec; 103(3):1007-11. PubMed ID: 16854456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endoglin (CD105) expression in angiogenesis of primary hepatocellular carcinomas: analysis using tissue microarrays and comparisons with CD34 and VEGF.
    Yao Y; Pan Y; Chen J; Sun X; Qiu Y; Ding Y
    Ann Clin Lab Sci; 2007; 37(1):39-48. PubMed ID: 17311868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The associations between serum VEGF, bFGF and endoglin levels with microvessel density and expression of proangiogenic factors in malignant and benign ovarian tumors.
    Szubert S; Moszynski R; Michalak S; Nowicki M; Sajdak S; Szpurek D
    Microvasc Res; 2016 Sep; 107():91-6. PubMed ID: 27312585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic relevance of CD105+ microvessel density in HNSCC patient outcome.
    Martone T; Rosso P; Albera R; Migliaretti G; Fraire F; Pignataro L; Pruneri G; Bellone G; Cortesina G
    Oral Oncol; 2005 Feb; 41(2):147-55. PubMed ID: 15695116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of endoglin (CD105) expression in ovarian carcinoma.
    Taskiran C; Erdem O; Onan A; Arisoy O; Acar A; Vural C; Erdem M; Ataoglu O; Guner H
    Int J Gynecol Cancer; 2006; 16(5):1789-93. PubMed ID: 17009973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microvessel Landscape Assessment in Pancreatic Ductal Adenocarcinoma: Unclear Value of Targeting Endoglin (CD105) as Prognostic Factor of Clinical Outcome.
    Lytras D; Leontara V; Kefala M; Foukas PG; Giannakou N; Pouliakis A; Dervenis C; Panayiotides IG; Karakitsos P
    Pancreas; 2015 Jan; 44(1):87-92. PubMed ID: 25058886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical evaluation of the microvascular density through the expression of TGF-beta (CD 105/endoglin) and CD 34 receptors and expression of the vascular endothelial growth factor (VEGF) in oligodendrogliomas.
    Netto GC; Bleil CB; Hilbig A; Coutinho LM
    Neuropathology; 2008 Feb; 28(1):17-23. PubMed ID: 18181830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody.
    Yao Y; Kubota T; Takeuchi H; Sato K
    Neuropathology; 2005 Sep; 25(3):201-6. PubMed ID: 16193836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic relevance of CD105-assessed microvessel density in laryngeal carcinoma.
    Zvrko E; Mikic A; Vuckovic L; Djukic V; Knezevic M
    Otolaryngol Head Neck Surg; 2009 Oct; 141(4):478-83. PubMed ID: 19786216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGF18 as a potential biomarker in serous and mucinous ovarian tumors.
    El-Gendi S; Abdelzaher E; Mostafa MF; Sheasha GA
    Tumour Biol; 2016 Mar; 37(3):3173-83. PubMed ID: 26427667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microtissue density prognostic factor evaluation based on antigens CD34 and CD 105 in ovarian cancer patients.
    Cwiklnska A; Sobstyl M; Kwasniewski W; Bednarek W
    Ann Agric Environ Med; 2013; 20(4):838-42. PubMed ID: 24364465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.